Tang Hua-Yu, Li Yu-Zhi, Tang Zhao-Chen, Jiang Quan-Wei, Zhao Yu
Second Ward of Orthopedics Department.
Department of Urology, First Affiliated Hospital of Jiamusi University.
Medicine (Baltimore). 2020 Jul 24;99(30):e21089. doi: 10.1097/MD.0000000000021089.
Ankylosing spondylitis (AS) is a very tricky orthopedic disorder. If such condition cannot be managed fairly well, it may significantly affect quality of life and even leads to disability among such population. A variety of studies have reported that alendronate is utilized for the treatment of AS. However, their results are still contrary, and no systematic review has addressed on this topic. Thus, this study will systematically assess the efficacy and safety of alendronate for the treatment of patients with AS.
A comprehensive literature search will be performed from the below electronic databases from their commencement to the January 31, 2020 without language and publication status limitations: PubMed, Embase, Cochrane Library, Web of Science, Allied and Complementary Medicine Database, WANGFANG, and China National Knowledge Infrastructure. Only randomized controlled trials focusing on the alendronate for the treatment of patients with AS will be considered for inclusion in this study. Two authors will independently select all identified records, extract essential data from all included studies, and appraise study quality for each eligible trial using Cochrane risk of bias. If any differences occur, another experienced author will be invited to solve them by discussion and a consensus decision will be made. We will implement RevMan 5.3 software to analyze the extracted data.
This study will summarize high-quality randomized controlled trials to assess the efficacy and safety of alendronate for the treatment of patients with AS through primary outcome of bone densitometry; and secondary outcomes of pain intensity, quality of life, disease activity, functional status, and adverse events.
This study will provide evidence to help determine whether alendronate is an effective and safe management for patient with AS or not.
INPLASY202040153.
强直性脊柱炎（AS）是一种非常棘手的骨科疾病。如果这种疾病不能得到很好的控制，可能会显著影响生活质量，甚至导致该人群残疾。各种研究报告称，阿仑膦酸盐被用于治疗AS。然而，它们的结果仍然相互矛盾，且尚无关于该主题的系统评价。因此，本研究将系统评估阿仑膦酸盐治疗AS患者的疗效和安全性。
将从以下电子数据库自开始至2020年1月31日进行全面的文献检索，不受语言和出版状态限制：PubMed、Embase、Cochrane图书馆、科学网、补充与替代医学数据库、万方和中国知网。本研究仅纳入聚焦阿仑膦酸盐治疗AS患者的随机对照试验。两名作者将独立筛选所有识别出的记录，从所有纳入研究中提取关键数据，并使用Cochrane偏倚风险评估每个符合条件试验的研究质量。如果出现任何分歧，将邀请另一位经验丰富的作者通过讨论解决，并达成共识决定。我们将使用RevMan 5.3软件分析提取的数据。
本研究将总结高质量随机对照试验，通过骨密度测量的主要结局以及疼痛强度、生活质量、疾病活动度、功能状态和不良事件的次要结局，评估阿仑膦酸盐治疗AS患者的疗效和安全性。
本研究将提供证据，以帮助确定阿仑膦酸盐对AS患者是否为有效且安全的治疗方法。
INPLASY202040153。
